TrovaGene, Inc. Announces that its NPM1 Technology is Now Part of Laboratory Corporation of America Holdings (LabCorp) (LH)'s and InVivoScribe Technologies, Inc.'s AML Cancer Testing Services  
3/31/2010 11:24:23 AM

SAN DIEGO--(BUSINESS WIRE)--TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that LabCorp, one of the world’s leading reference laboratories, (LabCorp, NYSE:LH), and InVivoScribe Technologies, a world leader in molecular hematopathology testing, have notified the Company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis of acute myelogenous leukemia (AML). TrovaGene has sublicensed the technology to these labs and will receive royalties based upon their testing revenue.